Novartis experiences significant revenue contraction as key pharmaceutical patents reach expiration, allowing generic manufacturers to capture substantial market share. The Swiss multinational reports a 12% decline in first-quarter profits, reflecting intensified competitive pressure in the global medicines sector. This downturn highlights the pharmaceutical industry's ongoing challenges with patent cliffs and the necessity for continuous innovation pipelines to maintain profitability in an increasingly competitive landscape.

Summary auto-generated by AI from the original publisher's content. Editorial standards.